Deuruxolitinib Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of deuruxolitinib during breastfeeding. Because deuruxolitinib is 91.5% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during deuruxolitinib therapy and for 1 week after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Deuruxolitinib
CAS Registry Number
1513883-39-0
Drug Class
Breast Feeding
Lactation
Milk, Human
Breast Feeding
Enzyme Inhibitors
Janus Kinase Inhibitors
JAK Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
